Stem cell transplantation can provide durable disease control in blastic plasmacytoid dendritic cell neoplasm: a retrospective study from the European Group for Blood and Marrow Transplantation.
Standard
Stem cell transplantation can provide durable disease control in blastic plasmacytoid dendritic cell neoplasm: a retrospective study from the European Group for Blood and Marrow Transplantation. / Roos-Weil, Damien; Dietrich, Sascha; Boumendil, Ariane; Polge, Emmanuelle; Bron, Dominique; Carreras, Enric; Arturo, Iriondo Atienza; Arcese, William; Beelen, Dietrich W; Cornelissen, Jan J; Kröger, Nicolaus; Milone, Giuseppe; Rossi, Giuseppe; Jardin, Fabrice; Peters, Christina; Rocha, Vanderson; Sureda, Anna; Mohty, Mohamad; Dreger, Peter; European Group for Blood and Marrow Transplantation.
In: BLOOD, Vol. 121, No. 3, 2013, p. 440-446.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Stem cell transplantation can provide durable disease control in blastic plasmacytoid dendritic cell neoplasm: a retrospective study from the European Group for Blood and Marrow Transplantation.
AU - Roos-Weil, Damien
AU - Dietrich, Sascha
AU - Boumendil, Ariane
AU - Polge, Emmanuelle
AU - Bron, Dominique
AU - Carreras, Enric
AU - Arturo, Iriondo Atienza
AU - Arcese, William
AU - Beelen, Dietrich W
AU - Cornelissen, Jan J
AU - Kröger, Nicolaus
AU - Milone, Giuseppe
AU - Rossi, Giuseppe
AU - Jardin, Fabrice
AU - Peters, Christina
AU - Rocha, Vanderson
AU - Sureda, Anna
AU - Mohty, Mohamad
AU - Dreger, Peter
AU - European Group for Blood and Marrow Transplantation
PY - 2013
Y1 - 2013
N2 - Patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN) have a poor prognosis with conventional chemotherapy. In the present study, we retrospectively analyzed the outcome of patients with BPDCN who underwent allogeneic stem cell transplantation (allo-SCT) or autologous stem cell transplantation (auto-SCT). A total of 39 patients (allo-SCT, n = 34; auto-SCT, n = 5) were identified in the European Group for Blood and Marrow Transplantation registry. The 34 allo-SCT patients had a median age of 41 years (range, 10-70) and received transplantations from sibling (n = 11) or unrelated donors (n = 23) between 2003 and 2009. MAC was used in 74% of patients. Nineteen allo-SCT patients (56%) received transplantations in first complete remission. The 3-year cumulative incidence of relapse, disease-free survival, and overall survival was 32%, 33%, and 41%, respectively. By univariate comparison, being in first remission at allo-SCT favorably influenced survival, whereas age, donor source, and chronic GVHD had no significant impact. We conclude that high-dose therapy followed by allo-SCT from related or unrelated donors can provide durable remission even in elderly patients with BPDCN. However, it remains to be shown if graft-versus-malignancy effects can contribute significantly to BPDCN control after allo-SCT.
AB - Patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN) have a poor prognosis with conventional chemotherapy. In the present study, we retrospectively analyzed the outcome of patients with BPDCN who underwent allogeneic stem cell transplantation (allo-SCT) or autologous stem cell transplantation (auto-SCT). A total of 39 patients (allo-SCT, n = 34; auto-SCT, n = 5) were identified in the European Group for Blood and Marrow Transplantation registry. The 34 allo-SCT patients had a median age of 41 years (range, 10-70) and received transplantations from sibling (n = 11) or unrelated donors (n = 23) between 2003 and 2009. MAC was used in 74% of patients. Nineteen allo-SCT patients (56%) received transplantations in first complete remission. The 3-year cumulative incidence of relapse, disease-free survival, and overall survival was 32%, 33%, and 41%, respectively. By univariate comparison, being in first remission at allo-SCT favorably influenced survival, whereas age, donor source, and chronic GVHD had no significant impact. We conclude that high-dose therapy followed by allo-SCT from related or unrelated donors can provide durable remission even in elderly patients with BPDCN. However, it remains to be shown if graft-versus-malignancy effects can contribute significantly to BPDCN control after allo-SCT.
KW - Adult
KW - Humans
KW - Male
KW - Aged
KW - Female
KW - Middle Aged
KW - Adolescent
KW - Young Adult
KW - Child
KW - Prognosis
KW - Follow-Up Studies
KW - Disease-Free Survival
KW - Incidence
KW - Retrospective Studies
KW - Recurrence
KW - Europe/epidemiology
KW - Hematopoietic Stem Cell Transplantation/methods
KW - Registries/statistics & numerical data
KW - Bone Marrow Transplantation/methods
KW - Dendritic Cells/pathology
KW - Graft vs Host Disease/mortality
KW - Hematologic Neoplasms/mortality/pathology/therapy
KW - Precursor Cell Lymphoblastic Leukemia-Lymphoma/mortality/pathology/therapy
KW - Adult
KW - Humans
KW - Male
KW - Aged
KW - Female
KW - Middle Aged
KW - Adolescent
KW - Young Adult
KW - Child
KW - Prognosis
KW - Follow-Up Studies
KW - Disease-Free Survival
KW - Incidence
KW - Retrospective Studies
KW - Recurrence
KW - Europe/epidemiology
KW - Hematopoietic Stem Cell Transplantation/methods
KW - Registries/statistics & numerical data
KW - Bone Marrow Transplantation/methods
KW - Dendritic Cells/pathology
KW - Graft vs Host Disease/mortality
KW - Hematologic Neoplasms/mortality/pathology/therapy
KW - Precursor Cell Lymphoblastic Leukemia-Lymphoma/mortality/pathology/therapy
M3 - SCORING: Journal article
VL - 121
SP - 440
EP - 446
JO - BLOOD
JF - BLOOD
SN - 0006-4971
IS - 3
ER -
